PROJECT SUMI (IARY (See instructions): The oropharynx is central to Kaposi sarcoma-assocaited herpesvirus (KSHV) infection;it is the primary site of viral replication, and saliva is the major route of KSHV transmission. Uncontrolled KSHV infection is associated with progression to KS. Some immunocompetent KSHV-infected people have frequent, high quantity oral replication, whereas others either rarely or never shed KSHV in saliva. This striking difference in the ability to control oral KSHV infection has clear implications for viral transmission, but may also be important for disease progression, since oral replication is strongly correlated with subsequent KSHV viremia and dissemination within the host. KSHV replication and development of KS occur much more often among people with HIV and other immunodeficiencies, which demonstrates the critical role of the immune system for preventing KSHV-associated disease. It is unknown, however, which immune responses to KSHV are most relevant for controlling infection. Despite the importance of the oral cavity in KSHV infection, mucosal immunity against KSHV has not been well studied. Neither is it understood how HIV infection and antiretroviral therapy (ART) affect oral immune responses to KSHV. The overall goal of this project is to identify correlates of the mucosal immune response associated with control of oral KSHV infection and viremia, and define how they are impaired by HIV infection.
In Aim 1, mucosal immune effector mechanisms mediating control of KSHV infection in the oral cavity and blood will be identified. Cohorts of KSHV infected/ HIV-negative people infection will be followed in Uganda to quantify the levels of KSHV detected in saliva and blood, and correlate them with: (1) neutralizing antibody in saliva;(2) gama delta+ T cell responses;and (3) innate immune mediators in saliva.
In Aim 2, the effect of untreated HIV infection on mucosal immune responses to KSHV will be evaluated by comparing the frequency and strength of the immune effector mechanisms described in HIV-uninfected people in Aim 1 to those in a second cohort of HIV-infected/ART naive subjects. Finally, in Aim 3, it will be determined whether ART is able to normalize mucosal immune responses to KSHV bv following HIV-infected subiects before and after initiation of ART.
KS is the most common cancer in people infected with HIV. Moreover, in some parts of sub-Saharan Africa, such as Uganda, the clinical site for this study, KS is the most common cancer in the general population. Even with optimal therapy, complete resolution is only achieved in approximately half of patients, indicating the need for new strategies to prevent and treat KS.
|Garrigues, H Jacques; DeMaster, Laura K; Rubinchikova, Yelena E et al. (2014) KSHV attachment and entry are dependent on ?V?3 integrin localized to specific cell surface microdomains and do not correlate with the presence of heparan sulfate. Virology 464-465:118-33|
|Fontaine, Krystal A; Camarda, Roman; Lagunoff, Michael (2014) Vaccinia virus requires glutamine but not glucose for efficient replication. J Virol 88:4366-74|
|Garrigues, H Jacques; Rubinchikova, Yelena E; Rose, Timothy M (2014) KSHV cell attachment sites revealed by ultra sensitive tyramide signal amplification (TSA) localize to membrane microdomains that are up-regulated on mitotic cells. Virology 452-453:75-85|
|Gutierrez, Kimberley D; Morris, Valerie A; Wu, David et al. (2013) Ets-1 is required for the activation of VEGFR3 during latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol 87:6758-68|
|Morris, Valerie A; Punjabi, Almira S; Wells, Robert C et al. (2012) The KSHV viral IL-6 homolog is sufficient to induce blood to lymphatic endothelial cell differentiation. Virology 428:112-20|
|DiMaio, Terri A; Gutierrez, Kimberley D; Lagunoff, Michael (2011) Latent KSHV infection of endothelial cells induces integrin beta3 to activate angiogenic phenotypes. PLoS Pathog 7:e1002424|